Target intelligence / Profile preview

Neisseria meningitidis capsular polysaccharide (serogroup W) (NmW capsule or MenW capsule)

Target
NmW capsule or MenW capsule
Molecular classification
Polysaccharide, Bacterial capsular polysaccharide, Glycoconjugate vaccine antigen
01

Overview

The *Neisseria meningitidis* capsular polysaccharide (serogroup W) is a high-molecular-weight polymer consisting of alternating sialic acid and D-galactose units, linked by α-(2→6) and α-(1→4) glycosidic bonds[5]. The capsule is the major virulence factor for *N. meningitidis*, providing resistance to host immune defenses and underpinning the antigenic basis for serogroup W classification. Polysaccharide capsules are central to pathogenesis and form the antigenic target for conjugate vaccines designed to prevent invasive meningococcal disease[1][5][7]. Genes required for capsule biosynthesis and surface expression are organized in a chromosomal locus known as *cps*[1][6]. Conjugate vaccines incorporating the MenW capsule are widely used and mediate protection by inducing functional, serogroup-specific antibody responses[1][5][3]. If you require further molecular detail (e.g., specific linkage types, structural models), refer to high-resolution studies on capsular conformation[5].

Other names
MenW capsuleNmW capsuleserogroup W polysaccharideW-135 capsule
02

Mechanism of action

Induction of protective, serogroup-specific antibodies against the capsule, leading to complement-mediated killing of the bacterium Prevention of invasive infection via immune memory

03

Biological functions

Virulence determinant (enables immune evasion and systemic infection)Antigenic structure (basis for serogroup classification and immune recognition)
04

Disease associations

Infection (invasive meningococcal disease: sepsis, meningitis)
05

Safety considerations

Capsule switching may enable the bacterium to evade vaccine-induced immunity, decreasing long-term effectivenessRare risk of autoimmune reactions following vaccination; otherwise, vaccines are generally considered safe
06

Interacting drugs

Meningococcal conjugate vaccines (e.g., MenACWY, which incorporate serogroup W polysaccharide conjugated to tetanus or diphtheria toxoid carriers)
07

Biomarkers

Presence of anti-MenW capsular polysaccharide antibodies (used for monitoring vaccine response and immunity)PCR detection of the *cps* locus specific to MenW

Beyond the preview

Go deeper on Neisseria meningitidis capsular polysaccharide (serogroup W) (NmW capsule or MenW capsule).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neisseria meningitidis capsular polysaccharide (serogroup W) (NmW capsule or MenW capsule).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call